Alex Zhavoronkov

Last updated
Alex Zhavoronkov
Born
Riga, Latvia [1] [2]
Alma mater Queen's University at Kingston
Johns Hopkins University (JHU) [3]
Known forThe Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy
Scientific career
Fields aging, regenerative medicine, drug development, artificial intelligence
Institutions Insilico Medicine, Biogerontology Research Foundation

Alex Zhavoronkov (born Aleksandrs Zavoronkovs) [3] is a Latvian-born scientist and author working in biotechnology, regenerative medicine, and aging economics. He is the founder and CEO of Insilico Medicine, [4] [5] [6] and as of 2024, was also the director of the Biogerontology Research Foundation, [7] [8] a UK-based think-tank for aging research. Zhavoronkov has published a substantial number of papers, and books including The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy. [9] [10]

Contents

Biography

Early life, education, and career

Born in Latvia, [1] [2] [6] Zhavoronkov received two bachelor's degrees from Queen's University, [3] and worked in graphics processing before moving to the biotechnology field. [11] He received a master's degree in biotechnology from Johns Hopkins University, [6] [11] and a PhD in physics and mathematics from Moscow State University. [3] In the mid 2010s, he was an adjunct professor at the Moscow Institute of Physics and Technology. [12] As of 2024, he was an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging. [13] Zhavoronkov was named as a co-inventor on a patent issued in May 2013 for "systems and methods for communicating with a computer using brain activity patterns". [14] [15]

AI and medical research

In 2014, Zhavoronkov began work towards using "massive data sets and Al to significantly speed up the drug discovery process", [16] and established Insilico at Johns Hopkins University in Baltimore. [6] [11] [16] [17] [18] Tony Robbins and Peter Diamandis were early investors in Zhavoronkov's efforts. [16] Robbins wrote of Zhavoronkov that "researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology". [16]

In November 2017, Zhavoronkov proposed the application of the deep learning techniques and blockchain technology for managing human life data. [19] [20] [21]

In 2022, Zhavoronkov participated in a round of financing for Insilico Medicine that raised $60 million for the venture. [22] Zhavoronkov asserted at the time that the industry was "in 'biotechnology winter' where many companies are running out of cash and are dying", and that his fundraising was positioning the company for a coming "biotech spring". [22] AI writer Calum Chace described Zhavoronkov at the time as well-known within the longevity community "for his relentless focus". [1] In February 2023, Wesley J. Smith, writing for National Review , sharply criticized comments by Zhavoronkov, who had observed that organ transplants used to facilitate life extension could someday be provided by using human clones generated without cognitive functions. [23]

In June 2023, Zhavoronkov led Insilico's development of what he described as "the first fully generative AI drug to reach human clinical trials, and specifically Phase II trials with patients". [24]

Other AI and internet activities

In 2016, Zhavoronkov was the chief science officer for Beauty.AI, an artificial intelligence technology that evaluate people's external appearance through certain algorithms. In this role, he responded to concerns about ethnic bias in results generated by the platform by attributing them to a lack of data provided to it. [25]

In 2022, Zhavoronkov was an author of a paper titled Rapamycin in the context of Pascal's Wager: generative pre-trained transformer perspective, which was described as one of the first peer-reviewed published papers to formally credit ChatGPT as a coauthor. [26] Zhavoronkov reported that when he asked ChatGPT itself whether it should be named as a coauthor, "it responded with multiple compelling reasons as to why it should not". [26]

In May 2024, Zhavoronkov was noted to have funded production of a realistically animated rendition of a head transplant, with the face of the transplant subject being recognized as Zhavoronkov's own. This became a viral video on social media. [27]

Publications

Since 2010, Zhavoronkov has authored or co-authored over 250 scientific articles published in refereed journals and referenced in PubMed. [28] [29]

Books
Articles

Related Research Articles

Artificial intelligence (AI), in its broadest sense, is intelligence exhibited by machines, particularly computer systems. It is a field of research in computer science that develops and studies methods and software that enable machines to perceive their environment and uses learning and intelligence to take actions that maximize their chances of achieving defined goals. Such machines may be called AIs.

<span class="mw-page-title-main">Chatbot</span> Program that simulates conversation

A chatbot is a software application or web interface that is designed to mimic human conversation through text or voice interactions. Modern chatbots are typically online and use generative artificial intelligence systems that are capable of maintaining a conversation with a user in natural language and simulating the way a human would behave as a conversational partner. Such chatbots often use deep learning and natural language processing, but simpler chatbots have existed for decades.

Brian Manning Delaney is a venture investor and researcher in the biogerontology space. Delaney is a partner at the longevity biotech venture fund Emerging Longevity Ventures. Previously he was a philosophy professor and translator of the works of Hegel. He divides his time between Stockholm and the U.S.

Following is a list of topics related to life extension:

Charles Thomas Caskey, also known as C. Thomas Caskey, was an American internist who has been a medical Geneticist and biomedical researcher and entrepreneur. He was a Professor of Molecular and Human Genetics at Baylor College of Medicine, and served as editor of the Annual Review of Medicine from 2001 to 2019. He was a member of the editorial boards of the Proceedings of the National Academy of Sciences, Science, the Encyclopedia of Molecular Medicine and numerous other medical and scientific journals.

This is a timeline of artificial intelligence, sometimes alternatively called synthetic intelligence.

Artificial intelligence (AI) has been used in applications throughout industry and academia. Similar to electricity or computers, AI serves as a general-purpose technology that has numerous applications. Its applications span language translation, image recognition, decision-making, credit scoring, e-commerce and various other domains. AI which accommodates such technologies as machines being equipped perceive, understand, act and learning a scientific discipline.

<span class="mw-page-title-main">Geoffrey von Maltzahn</span> American inventor

Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics. He has over 200 bioengineering and biotechnology patents and applications.

Calico Life Sciences LLC is biotechnology company with a focus on the biology of aging, attempting to devise interventions that may enable people to lead longer and healthier lives. It is a subsidiary of Alphabet Inc.

Human Longevity, Inc. is a San Diego-based venture launched by Craig Venter and Peter Diamandis in 2013. Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging. The company received US$80 million in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016. It has made deals with drug companies Celgene and AstraZeneca to collaborate in its research.

<span class="mw-page-title-main">Artificial intelligence in healthcare</span> Overview of the use of artificial intelligence in healthcare

Artificial intelligence in healthcare is the application of artificial intelligence (AI) to copy human cognition in the analysis, presentation, and understanding of complex medical and health care data, or to exceed human capabilities by providing new ways to diagnose, treat, or prevent disease. Specifically, AI is the ability of computer algorithms to arrive at approximate conclusions based solely on input data.

<span class="mw-page-title-main">Insilico Medicine</span> Biotechnology company

Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.

Beauty.AI is a mobile beauty pageant for humans and a contest for programmers developing algorithms for evaluating human appearance. The mobile app and website created by Youth Laboratories that uses artificial intelligence technology to evaluate people's external appearance through certain algorithms, such as symmetry, facial blemishes, wrinkles, estimated age and age appearance, and comparisons to actors and models.

Regina Barzilay is an Israeli-American computer scientist. She is a professor at the Massachusetts Institute of Technology and a faculty lead for artificial intelligence at the MIT Jameel Clinic. Her research interests are in natural language processing and applications of deep learning to chemistry and oncology.

Ali Maximilian Ertürk is a neuroscientist, inventor, and artist living in Munich, Germany. He is the director of a new Helmholtz Institute on Tissue Engineering and Regenerative Medicine (iTERM) in Munich since July 2019 and professor at the medical faculty. After his undergraduate study at Bilkent University in Ankara, he joined Max-Planck-Institute for Neurobiology for his PhD and Genentech Inc. for postdoctoral research.

VITAL was a Board Management Software machine learning proprietary software developed by Aging Analytics, a company registered in Bristol (England) and dissolved in 2017. Andrew Garazha declared that the project aimed "through iterative releases and updates to create a piece of software capable of making autonomous investment decisions." According to Nick Dyer-Witheford, VITAL 1.0 was a "basic algorithm".

<span class="mw-page-title-main">Amy Karle</span> American artist

Amy Karle is an American artist, bioartist, and futurist whose work focuses on the relationship between technology and humanity, specifically how technology and biotechnology impact health, humanity, society, evolution, and the future. Karle combines science and technology with art and is known for using living tissue in her work.

Owkin is an AI biotech company that uses artificial intelligence to identify new treatments, optimize clinical trials and develop AI diagnostics. The company uses federated learning, a type of privacy preserving technology, to access multimodal patient data from academic institutions and hospitals to train its AI models for drug discovery, development, and diagnostics. Owkin has collaborated with pharmaceutical companies around the world to improve their therapeutic programs.

<span class="mw-page-title-main">ChatGPT</span> Chatbot and virtual assistant developed by OpenAI

ChatGPT is a chatbot and virtual assistant developed by OpenAI and launched on November 30, 2022. Based on large language models (LLMs), it enables users to refine and steer a conversation towards a desired length, format, style, level of detail, and language. Successive user prompts and replies are considered at each conversation stage as context.

Inflection AI, Inc. is a technology company which has developed a machine learning and generative artificial intelligence hardware and apps, founded in 2022. The company is structured as a public benefit corporation and is headquartered in Palo Alto, California.

References

  1. 1 2 3 Chace, Calum (November 9, 2022). "How Insilico Medicine Uses AI To Accelerate Drug Development". Forbes Magazine .
  2. 1 2 Smyth, Jamie (June 26, 2023). "Biotech begins human trials of drug designed by artificial intelligence". Financial Times .
  3. 1 2 3 4 "Alex Zhavoronkov Aims to Take Over the Drug Development World with AI". Genetic Engineering and Biotechnology News . June 20, 2023.
  4. ↑ Eric Smaley (2017). "AI-powered drug discovery captures pharma interest". Nature Biotechnology. 35 (7): 605. doi:10.1038/nbt0717-604. PMID   28700560. S2CID   205269847.
  5. ↑ Tan, Dawn; Baker, Jalelah Abu (January 4, 2023). "Big investors pour funds into longevity research, accelerating growth in field". CNA.
  6. 1 2 3 4 Matsuyama, Kanoko (November 14, 2023). "Race for first drug discovered by AI nears key milestone". The Japan Times .
  7. ↑ "Biogerontology Research Foundation Salutes Staff On Multi-Year Drug Development Agreement". Bioengineer.org. August 14, 2017. Retrieved 28 November 2017.
  8. ↑ Raiany Romanni, "Want to live to 150? The world needs more humans", The Boston Globe (April 2, 2023), p. K1, K5.
  9. 1 2 Scheffler, Daniel (July 9, 2013). "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy (review)". Edge Media. Archived from the original on September 3, 2014.
  10. 1 2 Tom Blackwell, "Cutting-edge science seeks treatment for age", Toronto National Post (February 6, 2021), p. As5.
  11. 1 2 3 Brazil, Rachel (7 December 2017). "Artificial Intelligence: will it change the way drugs are discovered?". Pharmaceutical Journal, the Journal of the Royal Pharmacological Society.
  12. ↑ "News: Neural network learns to select potential anticancer drugs". MIPT News. February 9, 2017.
  13. ↑ "A rather disruptive bunch". Buck Institute for Research on Aging. Retrieved June 23, 2024.
  14. ↑ USpatent 8442626B2,Alex Zavoronkov, Mikhail Bakhnyan,"Systems and methods for communicating with a computer using brain activity patterns",issued May 14, 2013
  15. ↑ Bobrov, P; Frolov, A; Cantor, C; Fedulova, I; Bakhnyan, M; Zhavoronkov, A (2011). "Brain-computer interface based on generation of visual images". PLOS ONE. 6 (6): e20674. Bibcode:2011PLoSO...620674B. doi: 10.1371/journal.pone.0020674 . PMC   3112189 . PMID   21695206.
  16. 1 2 3 4 Robbins, Tony; Diamandis, Peter H.; Hariri, Robert (2022). Life Force. Simon and Schuster. p. 556-57. ISBN   978-1982121709.
  17. ↑ Gantz, Sarah (February 23, 2017). "Insilico Medicine raises $10 million". The Baltimore Sun .
  18. ↑ Thomas, Uduak Grace (March 28, 2014). "GenomeWeb: In Silico Medicine Opens US Office, Prepares to Launch Drug Discovery Software for Aging Research Market" – via www.genomeweb.com.
  19. ↑ "Skolkovo scientist says AI and blockchain could accelerate biomedical research". old.sk.ru.
  20. ↑ "Bitcoin Tech Lets People Reclaim Their Data, Says Medical Startup". Inverse. December 7, 2017.
  21. ↑ Haskins, Caroline (December 6, 2017). "This Biotech Company Wants You to Give it Selfies and Blood Tests in Exchange for Cryptocurrency".
  22. 1 2 Liao, Rita (June 6, 2022). "Hong Kong's AI drug discovery firm Insilico closes $60M Series D". TechCrunch .
  23. ↑ Smith, Wesley J. (February 8, 2023). "Harvesting Clones to Live Forever Would Be Monstrous". National Review .
  24. ↑ Field, Hayden (June 29, 2023). "The first fully A.I.-generated drug enters clinical trials in human patients". CNBC .
  25. ↑ Pearson, Jordan (2016-09-05). "Why An AI-Judged Beauty Contest Picked Nearly All White Winners". Motherboard. Retrieved 2017-01-17.
  26. 1 2 Berenbaum, May R. (November 22, 2023). "Welcome, AI overlords?". Proceedings of the National Academy of Sciences of the United States of America (PNAS). Vol. 120, no. 48. doi:10.1073/pnas.2318980120.
  27. ↑ Regalado, Antonio (May 23, 2024). "That viral video showing a head transplant is a fake. But it might be real someday". MIT Technology Review.
  28. ↑ Google Scholar page of Alex Zhavoronkov, by publication date.
  29. ↑ PubMed Bibliography of Alex Zhavoronkov, Pubmed.
  30. ↑ "CBS Radio with Dan Raviv in Washington, DC". September 9, 2013. Event occurs at 1:45–5:20.
  31. ↑ "Interview with Aging Expert – Alex Zhavoronkov". Book Tour Radio. August 20, 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.